Filing Flows › Biofrontera (BFRI) › Q1 2026 › vs Q1 2025
Biofrontera (BFRI) Q1 2026 vs Q1 2025 (year over year)
Biofrontera's revenue rose $1.5M (+17%) from $8.6M in Q1 2025 to $10.1M in Q1 2026.
Biofrontera, Q1 2026: revenue $10.1M (+17% year over year), operating margin -42.8%, net loss $4.8M, operating cash flow −$70K. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $10.1M | $8.6M | $1.5M | +17% |
| Net loss | $4.8M | $4.2M | $549K | +13% |
| Costs & expenses | $14.8M | $13.1M | $1.7M | +13% |
| Operating costs | $14.4M | $13.1M | $1.3M | +10% |
| Interest & other, net | $432K | −$343K | $775K | — |
| Research & development | $900K | $1.2M | −$307K | -25% |
| SG&A | $11.0M | $8.7M | $2.3M | +27% |
| Other operating costs | $2.5M | $3.3M | −$765K | -23% |
| Operating cash sources | $4.8M | $4.2M | $549K | +13% |
| Depreciation & amortization | $55K | $29K | $26K | +90% |
| Share-based compensation | $342K | $239K | $103K | +43% |
| Working capital & other | $4.3M | −$182K | $4.5M | — |
| Cash used in operations | $70K | $4.1M | −$4.0M | -98% |
| Net loss absorbed | $4.8M | $4.2M | $549K | +13% |
Questions
How much did Biofrontera's revenue grow year over year in Q1 2026?
Biofrontera's revenue rose $1.5M (+17%) from $8.6M in Q1 2025 to $10.1M in Q1 2026.